Craig Adam R's Form 4 filing
Cti Biopharma Corp (CTIC) · filed Dec 2, 2021
- Accession no.
- 0000891293-21-000045
- Filed
- Dec 2, 2021
- Trade date
- Jun 30-Dec 2, 2021
- Filing delay
- 155 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market purchases total $5.34K. It was filed 155 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Craig Adam RCIK 0001339498 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 30, 2021 | common stock | AGrant or awardAcquired | +5,000 | $2.13 | +$10,650 | 10,000 | Direct | |
| Dec 2, 2021 | common stock | PPurchaseAcquired | +1,322 | $1.52 | +$2,009.44 | 11,322 | Direct | |
| Dec 2, 2021 | common stock | PPurchaseAcquired | +2,178 | $1.53 | +$3,332.34 | 13,500 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.